Huang, Y; Sompii-Montgomery, L; Patti, J; Pickering, A; Yasin, S; Do, T; Baker, E; Gao, D; Abdul-Aziz, R; Behrens, EM; Ting, T; Grom, AA; Towe, C; Schulert, GS. Disease Course, Treatments, and Outcomes of Children With Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease. Arthritis Care and Research. 2024; 76:328-339.

Peng, J; Dönnes, P; Ardoin, SP; Schanberg, LE; Lewandowski, L; Ardoin, S; Dewitt, EM; Rabinovich, CE; Ellis, J; Mieszkalski, K; Paepke-Tollefsrud, DE; Robinson, G; Jury, EC; Ciurtin, C. Atherosclerosis Progression in the APPLE Trial Can Be Predicted in Young People With Juvenile-Onset Systemic Lupus Erythematosus Using a Novel Lipid Metabolomic Signature. Arthritis and Rheumatology. 2024; 76:455-468.

Vega-Fernandez, P; Rogers, K; Sproles, A; Thornton, S; Huggins, J; Lovell, DJ; Cassedy, A; Meyers, AB; Ting, TV. Diagnostic Accuracy Study of the Pediatric-Specific Ultrasound Scoring System for the Knee Joint in Children With Juvenile Idiopathic Arthritis. Arthritis Care and Research. 2024; 76:251-258.

Schulert, G; Vastert, SJ; Grom, AA. The 4th NextGen therapies for SJIA and MAS: part 2 phenotypes of refractory SJIA and the landscape for clinical trials in refractory SJIA. Pediatric Rheumatology Online Journal. 2024; 21:87.

Grom, AA; Canna, SW; Abu-Arja, RF; Sinha, R; Peixoto, L; Cannizzaro, E; Chandrakasan, S; Driest, K; Marsh, R; Neven, B; Schulert, G; Silva, JM F; Wall, D; Zeilhofer, U. Part 5: Allogeneic HSCT in refractory SJIA with lung disease; recent cases from centers in North America & Europe. Pediatric Rheumatology Online Journal. 2024; 21:86.

de Benedetti, F; Grom, AA; Brunner, H. The 4th NextGen therapies for SJIA and MAS: part 3 clinical trials in refractory SJIA: historic controls as an alternative to a withdrawal design study. Pediatric Rheumatology Online Journal. 2024; 21:150.

Erkens, RG A; Calis, JJ A; Verwoerd, A; De Roock, S; Ter Haar, NM; Den Engelsman, G; Van der Veken, LT; Ernst, RF; Van Deutekom, HW M; Pickering, A; Schulert, GS; Grom, AA; Van Loosdregt, J; Vastert, SJ. Recombinant Interleukin-1 Receptor Antagonist Is an Effective First-Line Treatment Strategy in New-Onset Systemic Juvenile Idiopathic Arthritis, Irrespective of HLA-DRB1 Background and IL1RN Variants. Arthritis and Rheumatology. 2024; 76:119-129.

Verweyen, EL; Thakkar, K; Dhakal, S; Baker, E; Chetal, K; Schnell, D; Canna, S; Grom, AA; Salomonis, N; Schulert, GS. Population-level single-cell genomics reveals conserved gene programs in systemic juvenile idiopathic arthritis. The Journal of Clinical Investigation. 2023; 133.

Towe, C; Grom, AA; Schulert, GS. Diagnosis and Management of the Systemic Juvenile Idiopathic Arthritis Patient with Emerging Lung Disease. Pediatric Drugs. 2023; 25:649-658.

Shakoory, B; Geerlinks, A; Wilejto, M; Kernan, K; Hines, M; Romano, M; Piskin, D; Ravelli, A; Sinha, R; Aletaha, D; Goldbach-Mansky, R; de Benedetti, F; Marsh, RA; Canna, SW. The 2022 EULAR/ACR Points to Consider at the Early Stages of Diagnosis and Management of Suspected Haemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS). Arthritis and Rheumatology. 2023; 75:1714-1732.

Shakoory, B; Geerlinks, A; Wilejto, M; Kernan, K; Hines, M; Romano, M; Piskin, D; Ravelli, A; Sinha, R; Aletaha, D; Goldbach-Mansky, R; De Benedetti, F; Marsh, RA; Canna, SW. The 2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS). Annals of the Rheumatic Diseases. 2023; 82:1271-1285.

De Benedetti, F; Grom, A; Brogan, P; Bracaglia, C; Pardeo, M; Marucci, G; Eleftheriou, D; Papadopoulou, C; Schulert, G; Quartier, P; Asnaghi, V; Ballabio, M; Jacqmin, P; De Min, C. OP0166 LONG-TERM FOLLOW-UP OF PATIENTS ADMINISTERED EMAPALUMAB, AN ANTI–INTERFERON-Γ MONOCLONAL ANTIBODY, TO TREAT MACROPHAGE ACTIVATION SYNDROME (MAS) SECONDARY TO SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA). 2023; 110-111.

De Benedetti, F; Grom, AA; Brogan, PA; Bracaglia, C; Pardeo, M; Marucci, G; Eleftheriou, D; Papadopoulou, C; Schulert, GS; Quartier, P; Asnaghi, V; Ballabio, M; Jacqmin, P; De Min, C. Efficacy and safety of emapalumab in macrophage activation syndrome. Annals of the Rheumatic Diseases. 2023; 82:857-865.

Vega-Fernandez, P; Ting, TV; Mar, DA; Schapiro, AH; Deluna, MD; Saper, VE; Grom, AA; Schulert, GS; Fairchild, RM. Lung Ultrasound in Children With Systemic Juvenile Idiopathic Arthritis-Associated Interstitial Lung Disease. Arthritis Care and Research. 2023; 75:983-988.

Chimote, AA; Mayhew, C; Thornton, S; Wetzel, C; White, AN. Implementing Research Shared (Core) Facility Billing Systems. Journal of biomolecular techniques : JBT. 2022; 33.

Miraldi Utz, V; Angeles-Han, ST; Mwase, N; Cassedy, A; Hennard, T; Lovell, DJ; Lopper, S; Brunner, HI; Dosunmu, EO; Grom, AA; Henrickson, M; Huggins, JL; Sisk, RA; Ting, TV; Kaufman, AH. Alternative Biologic Therapy in Children Failing Conventional TNFα Inhibitors for Refractory, Noninfectious, Chronic Anterior Uveitis. American Journal of Ophthalmology. 2022; 244:183-195.

Chen, G; Deutsch, GH; Schulert, GS; Zheng, H; Jang, SR; Trapnell, B; Lee, PY; Macaubas, C; Ho, K; Schneider, C; Goldbach-Mansky, R; Khatri, P; Mellins, ED; Canna, SW. Identification of Distinct Inflammatory Programs and Biomarkers in Systemic Juvenile Idiopathic Arthritis and Related Lung Disease by Serum Proteome Analysis. Arthritis and Rheumatology. 2022; 74:1271-1283.

Back, JB; Martinez, L; Nettenstrom, L; Sheerar, D; Thornton, S. Establishing a biosafety plan for a flow cytometry shared resource laboratory. Cytometry. Part A : the journal of the International Society for Analytical Cytology. 2022; 101:380-386.

Chalhoub, NE; Wenderfer, SE; Levy, DM; Rouster-Stevens, K; Aggarwal, A; Savani, SI; Ruth, NM; Arkachaisri, T; Qiu, T; Merritt, A; Hoffmann, S; Hollander, M; Hom, C; Houk, L. International Consensus for the Dosing of Corticosteroids in Childhood-Onset Systemic Lupus Erythematosus With Proliferative Lupus Nephritis. Arthritis and Rheumatology. 2022; 74:263-273.

Angeles-Han, ST; Miraldi Utz, V; Thornton, S; Schulert, G; Rodriguez-Smith, J; Kauffman, A; Sproles, A; Mwase, N; Hennard, T; Grom, A; Altaye, M; Holland, GN. S100 proteins, cytokines, and chemokines as tear biomarkers in children with juvenile idiopathic arthritis-associated uveitis. Ocular Immunology and Inflammation (Informa). 2021; 29:1616-1620.

Gao, DK; Salomonis, N; Henderlight, M; Woods, C; Thakkar, K; Grom, AA; Thornton, S; Jordan, MB; Wikenheiser-Brokamp, KA; Schulert, GS. IFN-γ is essential for alveolar macrophage-driven pulmonary inflammation in macrophage activation syndrome. JCI insight. 2021; 6.

Kessel, C; Fall, N; Grom, A; de Jager, W; Vastert, S; Strippoli, R; Bracaglia, C; Sundberg, E; Horne, AC; Ehl, S; Kessel, K; Beutel, K; Foell, D; Holzinger, D. Definition and validation of serum biomarkers for optimal differentiation of hyperferritinaemic cytokine storm conditions in children: a retrospective cohort study. The Lancet. Rheumatology. 2021; 3:e563-e573.

Rodriguez-Smith, JJ; Verweyen, EL; Clay, GM; Esteban, YM; de Loizaga, SR; Baker, EJ; Do, T; Dhakal, S; Lang, SM; Grom, AA; Grier, D; Schulert, GS. Inflammatory biomarkers in COVID-19-associated multisystem inflammatory syndrome in children, Kawasaki disease, and macrophage activation syndrome: a cohort study. The Lancet. Rheumatology. 2021; 3:e574-e584.

Verweyen, EL; Pickering, A; Grom, AA; Schulert, GS. Distinct Gene Expression Signatures Characterize Strong Clinical Responders Versus Nonresponders to Canakinumab in Children With Systemic Juvenile Idiopathic Arthritis. Arthritis and Rheumatology. 2021; 73:1334-1340.

Cheung, P; Schaffert, S; Chang, SE; Dvorak, M; Donato, M; Macaubas, C; Foecke, MH; Li, TM; Zhang, L; Coan, JP; Mellins, ED; Khatri, P; Utz, PJ; Kuo, AJ. Repression of CTSG, ELANE and PRTN3-mediated histone H3 proteolytic cleavage promotes monocyte-to-macrophage differentiation. Nature Immunology. 2021; 22:711-722.

Luo, S; Clarke, SL N; Ramanan, AV; Thompson, SD; Langefeld, CD; Marion, MC; Grom, AA; Schooling, CM; Gaunt, TR; Yeung, SL A; Zheng, J. Platelet Glycoprotein Ib α-Chain as a Putative Therapeutic Target for Juvenile Idiopathic Arthritis: A Mendelian Randomization Study. Arthritis and Rheumatology. 2021; 73:693-701.

Daniels, K; Conway, A; Gardner, R; Martinez, L; Price, KM; Schneider, S; Sheridan, R; Srivastava, J; Thornton, S. Remote Training of SRL Users and Staff in a Global Pandemic. Cytometry. Part A : the journal of the International Society for Analytical Cytology. 2021; 99:42-50.

Aspland, AM; Douagi, I; Filby, A; Jellison, ER; Martinez, L; Shinko, D; Smith, AL; Tang, VA; Thornton, S. Biosafety during a pandemic: shared resource laboratories rise to the challenge. Cytometry. Part A : the journal of the International Society for Analytical Cytology. 2021; 99:68-80.

Aljaberi, N; Tronconi, E; Schulert, G; Grom, AA; Lovell, DJ; Huggins, JL; Henrickson, M; Brunner, HI. The use of S100 proteins testing in juvenile idiopathic arthritis and autoinflammatory diseases in a pediatric clinical setting: a retrospective analysis. Pediatric Rheumatology Online Journal. 2020; 18:7.

Lin, B; Berard, R; Al Rasheed, A; Aladba, B; Kranzusch, PJ; Henderlight, M; Grom, A; Kahle, D; Torreggiani, S; Aue, AG; Mitchell, J; de Jesus, AA; Schulert, GS; Goldbach-Mansky, R. A novel STING1 variant causes a recessive form of STING-associated vasculopathy with onset in infancy (SAVI). Journal of Allergy and Clinical Immunology. 2020; 146:1204-1208.e6.

Box, A; Delay, M; Tighe, S; Chittur, SV; Bergeron, A; Cochran, M; Lopez, P; Meyer, EM; Saluk, A; Thornton, S; Brundage, K. Evaluating the Effects of Cell Sorting on Gene Expression. Journal of biomolecular techniques : JBT. 2020.

Box, A; DeLay, M; Tighe, S; Chittur, SV; Bergeron, A; Cochran, M; Lopez, P; Meyer, EM; Saluk, A; Thornton, S; Brundage, K. Evaluating the Effects of Cell Sorting on Gene Expression. Journal of biomolecular techniques : JBT. 2020; 31:100-111.

Canna, SW; Schulert, GS; de Jesus, A; Pickering, A; Brunner, H; Gadina, M; Levine, S; Goldbach-Mansky, R; Boutelle, J; Sinha, R; DeBenedetti, F; Grom, A; Participants, N. Proceedings from the 2nd Next Gen Therapies for Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome symposium held on October 3-4, 2019. Pediatric Rheumatology Online Journal. 2020; 18:53.

Henderson, LA; Canna, SW; Schulert, GS; Volpi, S; Lee, PY; Kernan, KF; Caricchio, R; Mahmud, S; Hazen, MM; Halyabar, O; De Benedetti, F; Behrens, EM; Cron, RQ; Nigrovic, PA. On the Alert for Cytokine Storm: Immunopathology in COVID-19. Arthritis and Rheumatology. 2020; 72:1059-1063.

Locatelli, F; Jordan, MB; Allen, C; Cesaro, S; Rizzari, C; Rao, A; Degar, B; Garrington, TP; Sevilla, J; Putti, M; Lapeyre, G; Jacqmin, P; Ballabio, M; de Min, C. Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis. The New England Journal of Medicine. 2020; 382:1811-1822.

de Jesus, AA; Hou, Y; Brooks, S; Malle, L; Biancotto, A; Huang, Y; Calvo, KR; Marrero, B; Moir, S; Oler, AJ; van Royen-Kerkhof, A; Muskardin, TW; Canna, SW; Goldbach-Mansky, R. Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases. The Journal of Clinical Investigation. 2020; 130:1669-1682.

Verweyen, E; Holzinger, D; Weinhage, T; Hinze, C; Wittkowski, H; Pickkers, P; Albeituni, S; Verbist, K; Nichols, KE; Schulert, G; Grom, A; Foell, D; Kessel, C. Synergistic Signaling of TLR and IFNα/β Facilitates Escape of IL-18 Expression from Endotoxin Tolerance. American Journal of Respiratory and Critical Care Medicine. 2020; 201:526-539.

Yasin, S; Solomon, K; Canna, SW; Girard-Guyonvarc'h, C; Gabay, C; Schiffrin, E; Sleight, A; Grom, AA; Schulert, GS. IL-18 as therapeutic target in a patient with resistant systemic juvenile idiopathic arthritis and recurrent macrophage activation syndrome. Rheumatology. 2020; 59:442-445.

Yasin, S; Fall, N; Brown, RA; Henderlight, M; Canna, SW; Girard-Guyonvarc'h, C; Gabay, C; Grom, AA; Schulert, GS. IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndrome. Rheumatology. 2020; 59:361-366.